Hepatitis | Targeted Therapies

2011: A Breakthrough Year in HCV Treatment

May 02, 2012

Clinical Articles

The medical community welcomed two new direct-acting antiviral (DAA) agents for HCV—telaprevir (Incivek, Vertex Pharmaceuticals Incorporated) and boceprevir (Victrelis, Merck & Co., Inc.)—with an excitement that hadn’t been seen since 1990.

What’s In the HCV Pipeline?

May 02, 2012

Clinical Articles

It’s always hard to know how many new therapies will make it all the way through a drug development pipeline.There are 12 combination therapies in phase II trials, 19 individual agents in phase II, and five more in phase III.